Regulations.gov document
Product-Specific Guidance for Cilastatin Sodium; Imipenem; Relebactam; Draft Guidance for…
Notice · FDA-2007-D-0369 · posted Jul 19, 2021
Key facts
| Document ID | FDA-2007-D-0369-0554 |
|---|---|
| Title | Product-Specific Guidance for Cilastatin Sodium; Imipenem; Relebactam; Draft Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2007-D-0369 |
| Posted | Jul 19, 2021 |
| Federal Register citation | 86 FR 38102 |
| FR document number | 2021-15170 |
| Comment period opens | Jul 19, 2021 |
| Comments due | Sep 18, 2021 |
| Effective date | Jul 19, 2021 |
At a glance
- 1–9 Pages
- No Open for comment
- 100–999 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: